Markwin Velders

Markwin is an independent entrepreneur with 25 years of experience, in the fields of research, development, operations and management. After transferring from the US academical to the Dutch biopharmaceutical sector, Markwin served, among several other management positions, four years as CSO at the Dutch biotech company AM-Pharma, with responsibility for R&D. In 2013 he consulted with the Dutch biotech T-Cell Factory (TCF) where he played a key role in the acquisition of the company to form Kite Pharma EU B.V. Markwin following joined Kite in 2015 as VP Operations where he managed the R&D of new T cell receptors alongside the implementation of Kite’s new manufacturing facility for cell therapy in the Netherlands. In addition, Markwin is former chairman of the supervisory board of HollandBio, the branch association for Biotech in the Netherlands and supervisory board member at ISA Pharmaceuticals in Leiden.

Markwin was awarded a PhD in Molecular Immunology from Leiden University in the Netherlands.